GlaxoSmithKline Pharmaceuticals Management Change
GSK Pharmaceuticals reported the resignation of Director Subesh Williams and the re-appointment of Executive Director Bhushan Akshikar effective December 1, 2026.
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
5 announcements with these filters
GSK Pharmaceuticals reported the resignation of Director Subesh Williams and the re-appointment of Executive Director Bhushan Akshikar effective December 1, 2026.
Dr. Simrat Sohal resigned as Compliance Officer of GlaxoSmithKline Pharmaceuticals, effective August 5, 2026. This transition requires the company to appoint a successor for regulatory compliance.
GlaxoSmithKline Pharmaceuticals Limited appointed Mr. Vinay Subramanian as Commercial Head - Oncology, effective April 20, 2026. Mr. Subramanian brings 24 years of experience from Roche, GE Healthcare, and Pfizer. This leadership addition strengthens the company's oncology portfolio management and strategic business development in India.
GlaxoSmithKline Pharmaceuticals Limited has appointed Mr. Ronojit Biswas as an Executive Director for a three-year term starting April 1, 2026. A seasoned finance leader with over 25 years of global GSK experience, he previously served as CFO for GSK's Brazil and Vietnam operations.
GlaxoSmithKline Pharmaceuticals Ltd appointed Mr. Vinay Subramanian as Commercial Head – Oncology and Senior Management Personnel, effective April 20, 2026. Subramanian brings over 24 years of experience from Roche, GE Healthcare, and Pfizer. This leadership addition strengthens the company's oncology business segment and strategic management team in Mumbai.